Merck's $688M Vytorin Settlement Wins Judge's Nod

Law360, New York (October 1, 2013, 9:39 PM EDT) -- A New Jersey federal judge on Tuesday approved a $688 million settlement to settle claims that Merck & Co. Inc. and its subsidiary Schering-Plough Corp. concealed test results on the efficacy of their anti-cholesterol drug Vytorin, while also awarding $140 million in attorneys’ fees.

U.S. District Court Judge Dennis M. Cavanaugh signed a trio of orders Tuesday, one approving the $688 million settlement Merck and Schering-Plough offered in February just prior to the class action’s trial date, and two more to grant attorneys’ fees and court...
To view the full article, register now.